Country: Canada
Language: English
Source: Health Canada
NORTRIPTYLINE (NORTRIPTYLINE HYDROCHLORIDE)
APOTEX INC
N06AA10
NORTRIPTYLINE
10MG
CAPSULE
NORTRIPTYLINE (NORTRIPTYLINE HYDROCHLORIDE) 10MG
ORAL
100
Prescription
TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0102630002; AHFS:
APPROVED
2021-04-06
_NORTRIPTYLINE (_ _Nortriptyline Hydrochloride Capsules_ _) _ _ _ _ _ _ _ _ _ _ Page 1 of 33_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR NORTRIPTYLINE Nortriptyline Hydrochloride Capsules Capsules, 10 mg and 25 mg, Oral USP Antidepressant APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: APR 01, 2021 Date of Revision: APRIL 5, 2023 Submission Control Number: 269184 _NORTRIPTYLINE (_ _Nortriptyline Hydrochloride Capsules_ _) _ _ _ _ _ _ _ _ _ _ Page 2 of 33_ _ _ RECENT MAJOR LABEL CHANGES N/A N/A TABLE OF CONTENTS _ _ SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED._ _ RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATION ................................................................................................................. 4 1.1 PEDIATRICS ................................................................................................................ 4 1.2 GERIATRICS ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS ..................................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 DOSING CONSIDERATIONS ............................................................................................ 5 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT ....................................................... 5 4.4 ADMINISTRATION .............................. Read the complete document